Dr. Shinichiro (Shin) Fuse, is Partner and Managing Director at TPG Life Sciences Innovation. He co-leads life sciences venture investments at TPG and serves on the Board of Directors at Santa Ana Bio and Sudo Biosciences. Previously, he was Managing Director at MPM Capital, where he served on the investment committee of the Oncology Impact Fund (OIF) and BioVentures Funds. Shin served on the Board of Directors of Orna Therapeutics, iOmx Therapeutics, Triplet Therapeutics and ReNAgade Therapeutics, and as a board observer for ElevateBio and Repare Therapeutics. Shin also played operational roles at MPM portfolio companies as the interim CEO of Orna Therapeutics and interim/founding SVP of Business Development at ElevateBio.​

Prior to joining MPM, he was Director of Business Development at bluebird bio, where he was instrumental in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, and genome editing. Previously, he was at Campbell Alliance (Syneos Health) as a life science strategy consultant. He currently serves on the Board of Advisors of the Guarini School of Graduate and Advanced Studies at Dartmouth College.​

Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, an M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.​